Pfizer and Moderna last week reported preliminary results from late-stage trials showing their vaccines were almost 95 per cent effective. But, unlike its rivals, the AstraZeneca vaccine doesn't have to be stored at ultra-cold temperatures, making it easier to distribute, especially in developing countries. The vaccine is said to be 90 per cent effective if correct protocol is followed and is cheaper than its rivals. A half-dose of the vaccine followed by a full dose at least one month later was 90 per cent effective. A researcher at the Jenner Institute in Oxford, England, works on the coronavirus vaccine developed by AstraZeneca and Oxford University.

Source: New Zealand Herald November 23, 2020 16:52 UTC